Meeting
2016 Gastrointestinal Cancers Symposium
Treatment patterns and outcomes in patients with KRAS wild type (WT) metastatic colorectal cancer (mCRC) treated in first line with bevacizumab (B) or cetuximab (C) containing regimens.
Authors
Arthur C. Houts
Vector Oncology, Memphis, TN
Arthur C. Houts , Sarika Ogale , Nicolas Sommer , Mark Stephen Walker
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Prevention, Diagnosis, and Screening
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 550)
DOI
10.1200/jco.2016.34.4_suppl.550
Abstract #
550
Poster Bd #
C19
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
A randomized phase II study to investigate the deepness of response (DpR) of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer (mCRC) patients with RAS wild-type tumors: DEEPER.
First Author: Akihito Tsuji
Poster
2015 ASCO Annual Meeting
A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405.
First Author: Federico Innocenti
Poster
2015 Gastrointestinal Cancers Symposium
Triplet chemotherapy (TC) with FOLFIRINOX regimen in metastatic colorectal cancer (mCRC): Experience of two French centres.
First Author: Emmanuelle Samalin
Poster
2014 ASCO Annual Meeting
Second-line therapies in patients with KRAS wild-type metastatic colorectal cancer (mCRC) after first-line therapy with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK0306 (FIRE 3) trial.
First Author: Dominik Paul Modest